Literature DB >> 27151053

Parkinsonism as a side effect of infliximab.

Jakob Nørgaard Henriksen1, Bengt Oluf Mikael Eriksson2.   

Abstract

We present a case of a 64-year-old man with Crohn's disease who developed parkinsonism after starting treatment with infliximab (Remicade). The patient had a 30-year history of Crohn's disease with previous surgical procedures and treatment with methotrexate. Treatment was augmented with infliximab, and 3 days after the first dose of 400 mg, a resting tremor began in the left leg. Over 4 months, symptoms progressed and now involved the right leg as well as both hands. There was no clinical effect of infliximab treatment, and the treatment was withdrawn 4 months later. The patient then experienced gradual, but continual, improvement of the resting tremor after withdrawal of infliximab. To the best of our knowledge, this is the first case report describing a patient developing parkinsonism after starting treatment with infliximab, with symptoms remitting on discontinuation. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27151053      PMCID: PMC4885252          DOI: 10.1136/bcr-2016-214802

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.

Authors:  P Hrycaj; I Korczowska; J K Łacki
Journal:  Rheumatology (Oxford)       Date:  2003-05       Impact factor: 7.580

2.  Vagotomy and subsequent risk of Parkinson's disease.

Authors:  Elisabeth Svensson; Erzsébet Horváth-Puhó; Reimar W Thomsen; Jens Christian Djurhuus; Lars Pedersen; Per Borghammer; Henrik Toft Sørensen
Journal:  Ann Neurol       Date:  2015-07-17       Impact factor: 10.422

Review 3.  Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.

Authors:  Louise M Collins; André Toulouse; Thomas J Connor; Yvonne M Nolan
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

4.  Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.

Authors:  Ida Vind; Lene Riis; Tine Jess; Elisabeth Knudsen; Natalia Pedersen; Margarita Elkjaer; Inger Bak Andersen; Vibeke Wewer; Peter Nørregaard; Flemming Moesgaard; Flemming Bendtsen; Pia Munkholm
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

5.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

6.  Genetic comorbidities in Parkinson's disease.

Authors:  Mike A Nalls; Mohamad Saad; Alastair J Noyce; Margaux F Keller; Anette Schrag; Jonathan P Bestwick; Bryan J Traynor; J Raphael Gibbs; Dena G Hernandez; Mark R Cookson; Huw R Morris; Nigel Williams; Thomas Gasser; Peter Heutink; Nick Wood; John Hardy; Maria Martinez; Andrew B Singleton
Journal:  Hum Mol Genet       Date:  2013-09-20       Impact factor: 6.150

7.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16

Review 8.  Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.

Authors:  Nin Bajaj; Robert A Hauser; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

  8 in total
  1 in total

1.  Protective Effect of Pogostone on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis via Inhibition of T Helper Cell.

Authors:  Jiyan Su; Cailan Li; Xiuting Yu; Guanghua Yang; Jianhua Deng; Ziren Su; Huifang Zeng; Jiannan Chen; Xiaojun Zhang; Xiaoping Lai
Journal:  Front Pharmacol       Date:  2017-11-17       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.